Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid…
By B. Cheson, John M. Bennett, K. Kopecky, T. Büchner, C. Willman, E. Estey, C. A. Schiffer, H. Doehner, Martin S. Tallman, T. A. Lister and 10 more. Journal of Clinical Oncology, 2003
2,786 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/75496c6ac509978e82915aa879b290e2b383f343
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
Citations in the corpus
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, neutral): “Median number of courses (range) 5 (1-18) 8 (1-17) 9 (1-15)”
- Acute Myeloid Leukemia: Epidemiology and Etiology (2006, neutral): “"The true secondary AML" has been recommended to be referred to patients who have a clear clinical history of prior myelodysplastic syndrome (MDS), myeloproliferative disorder, or exposure to potentially leukemogenic therapies or agents; it is thus a rather broad category [56] .”
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia (2016, methodology): “Clinical responses were defined by the revised IWG criteria for AML (31).”
- Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (2012, methodology): “Remission was evaluated by using modified 2003 International Working Group criteria.(15) Morphologic CR with incomplete blood count recovery was also recorded.”
- Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. (2004, neutral): “Elevated serum LDH, n 111 (%) 14 (26) 14 (25) 28 (25)”
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “Median d from diagnosis to trial entry (range) 21 (6-166)”
- Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML (2018, neutral): “Dose-escalation phase 4/33 (12) 5/35 (14) 12/78 (15)”